ENO2 and neoplasm: Factors which might cause this difference in our small study cohort in comparison to the RADIANT-3 trial data might be tumor grading, percentage of patients with high baseline NSE 1 × ULN or high baseline CgA 2 × ULN, as well as late treatment line with everolimus.